Eosinophilic Esophagitis
Conditions
Brief summary
Reduction/disappearance of eosinophil count in oesophageal mucosa (<15 EoE/HPF) after viscous budesonide therapy (T12)
Detailed description
Reduction of the symptomatic score calculated after therapy (T12), Reduction in endoscopic score calculated after therapy (T12), Monitoring and collection of adverse events (AEs) and severe adverse events (SAEs) (T6; T12)
Interventions
DRUGBUDESONIDE
Sponsors
University Hospital Consorziale Policlinico, University Of Bari Aldo Moro
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction/disappearance of eosinophil count in oesophageal mucosa (<15 EoE/HPF) after viscous budesonide therapy (T12) | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of the symptomatic score calculated after therapy (T12), Reduction in endoscopic score calculated after therapy (T12), Monitoring and collection of adverse events (AEs) and severe adverse events (SAEs) (T6; T12) | — |
Countries
Italy
Outcome results
None listed